Hologic Given a $27.00 Price Target at Goldman Sachs Group Inc. (HOLX)
Research analysts at Goldman Sachs Group Inc. set a $27.00 price objective on shares of Hologic (NASDAQ:HOLX) stock in a report released on Friday, Analyst Ratings News reports. Goldman Sachs Group Inc.’s target price would indicate a potential upside of 23.06% from the company’s current price.
Shares of Hologic (NASDAQ:HOLX) opened at 21.94 on Friday. Hologic has a one year low of $18.46 and a one year high of $23.96. The stock has a 50-day moving average of $22.2 and a 200-day moving average of $21.54. The company’s market cap is $5.992 billion.
Hologic (NASDAQ:HOLX) last released its earnings data on Monday, November 11th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.02. The company had revenue of $622.10 million for the quarter, compared to the consensus estimate of $624.40 million. During the same quarter in the previous year, the company posted $0.37 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts predict that Hologic will post $1.36 earnings per share for the current fiscal year.
A number of other firms have also recently commented on HOLX. Analysts at Zacks downgraded shares of Hologic from a “neutral” rating to an “underperform” rating in a research note to investors on Thursday, December 19th. They now have a $20.00 price target on the stock. Separately, analysts at Cowen and Company downgraded shares of Hologic from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, December 2nd. They now have a $24.00 price target on the stock, down previously from $25.50. Finally, analysts at Needham & Company reiterated a “buy” rating on shares of Hologic in a research note to investors on Thursday, November 21st. They now have a $26.00 price target on the stock. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $21.97.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.